View Future GrowthGetinge 과거 순이익 실적과거 기준 점검 4/6Getinge의 수입은 연평균 -13.7%의 비율로 감소해 온 반면, Medical Equipment 산업은 수입이 연평균 20.3% 감소했습니다. 매출은 연평균 5.8%의 비율로 증가해 왔습니다. Getinge의 자기자본이익률은 7.6%이고 순이익률은 6.9%입니다.핵심 정보-13.75%순이익 성장률-13.75%주당순이익(EPS) 성장률Medical Equipment 산업 성장률8.28%매출 성장률5.79%자기자본이익률7.65%순이익률6.92%다음 순이익 업데이트17 Jul 2026최근 과거 실적 업데이트공시 • Mar 26+ 3 more updatesGetinge AB (publ) to Report Q2, 2026 Results on Jul 17, 2026Getinge AB (publ) announced that they will report Q2, 2026 results on Jul 17, 2026Reported Earnings • Jul 21Second quarter 2025 earnings released: EPS: kr1.92 (vs kr1.88 in 2Q 2024)Second quarter 2025 results: EPS: kr1.92 (up from kr1.88 in 2Q 2024). Revenue: kr8.24b (flat on 2Q 2024). Net income: kr524.0m (up 2.1% from 2Q 2024). Profit margin: 6.4% (up from 6.2% in 2Q 2024). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Italy.공시 • Mar 28+ 1 more updateGetinge AB (publ) to Report Q3, 2025 Results on Oct 21, 2025Getinge AB (publ) announced that they will report Q3, 2025 results on Oct 21, 2025공시 • Dec 10Getinge AB (publ) to Report Q1, 2025 Results on Apr 22, 2025Getinge AB (publ) announced that they will report Q1, 2025 results on Apr 22, 2025모든 업데이트 보기Recent updates공시 • Jun 04Getinge Launches Vasoview Hemopro 3 Endoscopic Vessel Harvesting SystemGetinge announced the launch of the Vasoview Hemopro 3 Endoscopic Vessel Harvesting (EVH) System, including the Hemopro 3 Harvesting Tool and dedicated Hemopro 3 Power Supply. The system represents the latest evolution of Getinge's EVH platform, enhancing decades of experience supporting coronary artery bypass grafting (CABG) procedures. Endoscopic vessel harvesting is a minimally invasive technique used to obtain blood vessels, most commonly the saphenous vein or radial artery, for use in CABG surgery. Vessel harvesting plays a critical role in procedural success, as conduit quality and incision-related complications can significantly impact outcomes and recovery. Compared with traditional open harvesting methods, EVH has been associated with reduced wound complications, less postoperative pain, faster recovery, and improved cosmetic results. Getinge has completed an Initial Launch of the Vasoview Hemopro 3 EVH System and has received valuable, positive customer feedback. Getinge has continuously refined EVH technology with a focus on preserving conduit quality while improving the patient and clinician experience. Through close collaboration with vessel harvesting specialists, Getinge has advanced EVH technology in a deliberate, user-driven way, ensuring solutions evolve alongside clinical practice. The Vasoview Hemopro 3 system incorporates targeted enhancements across ergonomics, energy control, visualization, and workflow efficiency, informed by input from more than 100 vessel harvesting specialists worldwide. A redesigned Harvesting Tool features an ergonomic, game-controller-style handle and a soft-touch Activation Toggle that allows activation with minimal force and multiple hand positions, supporting clinician comfort and control throughout the procedure. The system also introduces simplified connectivity through an integrated Harvesting Tool Power Cable, providing a one-click connection to the new Vasoview Hemopro 3 Power Supply and eliminating the need for extension cable sterilization. The dedicated Power Supply is designed to deliver consistent energy and promote efficient cut-and-cautery performance with minimal downtime. Hemopro 3 includes features which support consistent visibility, safety, and workflow efficiency during EVH. Vasoview Hemopro 3 is launching in the U.S., with a training supported rollout available for U.S. customers. Getinge plans a phased expansion outside the U.S., with availability in additional markets to follow based on regulatory approvals and market readiness. Vasoview Hemopro 2 will continue to be available as Getinge rollout availability of Vasoview Hemopro 3.Recent Insider Transactions • May 31CEO, President & Director recently bought €436k worth of stockOn the 29th of May, Mattias Perjos bought around 25k shares on-market at roughly €17.43 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Mattias has been a buyer over the last 12 months, purchasing a net total of €715k worth in shares.Valuation Update With 7 Day Price Move • May 22Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €18.75, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 19x in the Medical Equipment industry in Italy. Total returns to shareholders of 8.3% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €32.79 per share.New Risk • May 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.2% average weekly change).공시 • Apr 22+ 1 more updateGetinge AB (publ) Approves Dividend, Payable from April 28, 2026Getinge AB (publ) approved the Dividend payment at its Annual General Meeting held on April 21, 2026. In accordance with the proposal by the Board of Directors and the CEO, the AGM resolved to declare a dividend of SEK 4.75 per share. April 23, 2026 was determined as record date for dividend. The dividend is expected to be distributed by Euroclear Sweden AB starting April 28, 2026.공시 • Apr 10Getinge AB (publ) (OM:GETI B) acquired Pennamed Limited.Getinge AB (publ) (OM:GETI B) acquired Pennamed Limited on April 8, 2026. The acquisition strengthens Getinge’s offering to endoscopy units across the United Kingdom (UK) by combining Pennamed’s established consumables portfolio and strong customer relationships with Getinge’s expertise in endoscope reprocessing, infection control, and washer-disinfector technology. Getinge and Pennamed has combined 350 employees. Abi Godfrey, Alex Parry and Matt Harvey of Grant Thornton UK LLP acted as accountants for Pennamed Limited. Emma Orriss and Nigel Beckwith of Gosschalks LLP acted as legal advisors for Pennamed Limited. Covington & Burling Llp acted as legal advisor and Ernst & Young AB acted as accountant for Getinge AB. Getinge AB (publ) (OM:GETI B) completed the acquisition of Pennamed Limited on April 8, 2026.공시 • Mar 26+ 3 more updatesGetinge AB (publ) to Report Q2, 2026 Results on Jul 17, 2026Getinge AB (publ) announced that they will report Q2, 2026 results on Jul 17, 2026공시 • Mar 12Getinge AB (publ) Announces Malin Persson Declines Re-Election as Board Member, Effective April 21, 2026Getinge AB (publ) at its Annual General Meeting to be held on April 21, 2026, announced Malin Persson has declined re-election as board member.Declared Dividend • Feb 24Dividend of kr4.75 announcedShareholders will receive a dividend of kr4.75. Ex-date: 22nd April 2026 Payment date: 28th April 2026 Dividend yield will be 25%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (57% earnings payout ratio) and cash flows (49% cash payout ratio). The dividend has increased by an average of 5.4% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 47% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Board Change • Feb 24Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 7 highly experienced directors. Director Ulrika Dellby was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Jan 28Getinge AB (publ), Annual General Meeting, Apr 21, 2026Getinge AB (publ), Annual General Meeting, Apr 21, 2026.공시 • Jan 27Getinge AB (Publ) Proposes DividendGetinge AB (publ) announced the proposal of dividend per share of SEK 4.75 (4.60).공시 • Dec 19Getinge AB Announces Malin Persson Declines Re-Election to the BoardGetinge AB announced that Malin Persson, a board member since 2014, has announced that she will not be available for re-election to the board in 2026.Board Change • Dec 11Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 7 highly experienced directors. Director Ulrika Dellby was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 19Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 7 highly experienced directors. Director Ulrika Dellby was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Oct 21Getinge AB (Publ) Reaffirms Earnings Guidance for the Year 2025Getinge AB (publ) reaffirmed earnings guidance for the year 2025. The company remain with expectation for organic net sales growth to be in the range of 2% to 5% and long-term financial target of over 12% EPS growth is also intact despite the headwind from tariffs and currency.Reported Earnings • Jul 21Second quarter 2025 earnings released: EPS: kr1.92 (vs kr1.88 in 2Q 2024)Second quarter 2025 results: EPS: kr1.92 (up from kr1.88 in 2Q 2024). Revenue: kr8.24b (flat on 2Q 2024). Net income: kr524.0m (up 2.1% from 2Q 2024). Profit margin: 6.4% (up from 6.2% in 2Q 2024). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Italy.공시 • Jul 02Getinge AB (publ)(OM:GETI B) dropped from OMX Stockholm 30 IndexGetinge AB (publ) has been dropped from the OMX OMX Stockholm 30 Index공시 • Apr 23+ 1 more updateGetinge AB (publ) Approves Dividend, Payable on April 29, 2025Getinge AB (publ) at its AGM held on April 22, 2025 approved dividend of SEK 4.60 per share. April 24, 2025 was determined as record date for dividend. The dividend is expected to be distributed by Euroclear Sweden AB starting Tuesday April 29, 2025.공시 • Mar 28+ 1 more updateGetinge AB (publ) to Report Q3, 2025 Results on Oct 21, 2025Getinge AB (publ) announced that they will report Q3, 2025 results on Oct 21, 2025공시 • Mar 18Getinge Introduces Neural Pressure Support for the Servo-U Ventilator SystemGetinge announces the launch of its latest innovation in ICU ventilation – Neural Pressure Support (NPS) – available for both invasive and non-invasive ventilation. Building on its most personalized ventilation modes, NAVA and NIV NAVA, these two new NPS modes offer clinicians more options to provide personalized ventilation that aims to protect both the lungs and diaphragm. For years, Getinge has been market-driving when it comes to developing first-of-its-kind intensive care ventilation modes. The medtech company is introducing NPS and NIV NPS to widen its neurally controlled ventilation offering. The new Neural Pressure Support modes give clinicians the opportunity to deliver classical pressure support ventilation, enhanced with neural trigger and breath termination in synchrony with diaphragmatic muscle activity. This may be particularly beneficial for complex and challenging ICU patient groups, such as obstructive COPD patients requiring instant synchronization and fast pressurization, and restrictive ARDS patients with stiff lungs and an excessive respiratory drive.공시 • Jan 29Getinge AB (publ), Annual General Meeting, Apr 22, 2025Getinge AB (publ), Annual General Meeting, Apr 22, 2025. Location: halmstad Sweden공시 • Dec 10Getinge AB (publ) to Report Q1, 2025 Results on Apr 22, 2025Getinge AB (publ) announced that they will report Q1, 2025 results on Apr 22, 2025매출 및 비용 세부 내역Getinge가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이BIT:1GETI 매출, 비용 및 순이익 (SEK Millions)날짜매출순이익일반관리비연구개발비31 Mar 2634,0922,35910,4231,46231 Dec 2534,9692,25810,6371,45230 Sep 2535,8542,05410,8371,41430 Jun 2535,4981,49010,7921,42631 Mar 2535,5661,47910,8321,43831 Dec 2434,7591,63810,6331,43130 Sep 2433,5911,69110,3421,33030 Jun 2433,3282,58410,2351,29231 Mar 2432,1992,2859,9561,20731 Dec 2331,8272,4129,6811,19230 Sep 2330,4232,2519,2601,25830 Jun 2329,7562,1549,0041,23231 Mar 2329,2512,5438,6721,22831 Dec 2228,2922,4918,3861,18530 Sep 2227,7812,7078,2401,00830 Jun 2227,1462,6658,06095231 Mar 2227,0622,8608,00590331 Dec 2127,0492,9707,92785130 Sep 2127,9003,2928,09089130 Jun 2129,5713,9168,22189931 Mar 2129,9553,6128,3901,03531 Dec 2029,8193,2398,7831,03330 Sep 2029,4783,0508,83095230 Jun 2027,7381,8788,95892031 Mar 2027,0441,4879,01775731 Dec 1926,5591,2228,85476230 Sep 1925,9511,0308,64474430 Jun 1925,398-6328,62872431 Mar 1924,852-6548,45571831 Dec 1824,172-9678,29269130 Sep 1823,653-7278,15767630 Jun 1822,9148477,86767031 Mar 1822,5526767,74764231 Dec 1722,4951,0967,74059430 Sep 1717,0615965,85850430 Jun 1719,0463906,36049631 Mar 1720,6047016,78350031 Dec 1622,1706987,20153830 Sep 1629,6501,2039,51262830 Jun 1629,6461,4629,56162431 Mar 1629,9001,4109,77760731 Dec 1530,2351,3909,90559830 Sep 1529,3031,4299,72257430 Jun 1528,6031,6229,471574양질의 수익: 1GETI는 고품질 수익을 보유하고 있습니다.이익 마진 증가: 1GETI의 현재 순 이익률 (6.9%)은 지난해 (4.2%)보다 높습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 1GETI의 수익은 지난 5년 동안 연평균 13.7% 감소했습니다.성장 가속화: 지난 1년간 1GETI 의 수익 증가율(59.5%)은 연간 평균(-13.7%)을 초과합니다.수익 대 산업: 1GETI의 지난 1년 수익 증가율(59.5%)은 Medical Equipment 업계의 -27%를 상회했습니다.자기자본이익률높은 ROE: 1GETI의 자본 수익률(7.6%)은 낮음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YHealthcare 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/17 18:43종가2026/06/17 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Getinge AB (publ)는 24명의 분석가가 다루고 있습니다. 이 중 10명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관null nullABG Sundal CollierScott BardoBerenbergDelphine Le LouetBernstein21명의 분석가 더 보기
공시 • Mar 26+ 3 more updatesGetinge AB (publ) to Report Q2, 2026 Results on Jul 17, 2026Getinge AB (publ) announced that they will report Q2, 2026 results on Jul 17, 2026
Reported Earnings • Jul 21Second quarter 2025 earnings released: EPS: kr1.92 (vs kr1.88 in 2Q 2024)Second quarter 2025 results: EPS: kr1.92 (up from kr1.88 in 2Q 2024). Revenue: kr8.24b (flat on 2Q 2024). Net income: kr524.0m (up 2.1% from 2Q 2024). Profit margin: 6.4% (up from 6.2% in 2Q 2024). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Italy.
공시 • Mar 28+ 1 more updateGetinge AB (publ) to Report Q3, 2025 Results on Oct 21, 2025Getinge AB (publ) announced that they will report Q3, 2025 results on Oct 21, 2025
공시 • Dec 10Getinge AB (publ) to Report Q1, 2025 Results on Apr 22, 2025Getinge AB (publ) announced that they will report Q1, 2025 results on Apr 22, 2025
공시 • Jun 04Getinge Launches Vasoview Hemopro 3 Endoscopic Vessel Harvesting SystemGetinge announced the launch of the Vasoview Hemopro 3 Endoscopic Vessel Harvesting (EVH) System, including the Hemopro 3 Harvesting Tool and dedicated Hemopro 3 Power Supply. The system represents the latest evolution of Getinge's EVH platform, enhancing decades of experience supporting coronary artery bypass grafting (CABG) procedures. Endoscopic vessel harvesting is a minimally invasive technique used to obtain blood vessels, most commonly the saphenous vein or radial artery, for use in CABG surgery. Vessel harvesting plays a critical role in procedural success, as conduit quality and incision-related complications can significantly impact outcomes and recovery. Compared with traditional open harvesting methods, EVH has been associated with reduced wound complications, less postoperative pain, faster recovery, and improved cosmetic results. Getinge has completed an Initial Launch of the Vasoview Hemopro 3 EVH System and has received valuable, positive customer feedback. Getinge has continuously refined EVH technology with a focus on preserving conduit quality while improving the patient and clinician experience. Through close collaboration with vessel harvesting specialists, Getinge has advanced EVH technology in a deliberate, user-driven way, ensuring solutions evolve alongside clinical practice. The Vasoview Hemopro 3 system incorporates targeted enhancements across ergonomics, energy control, visualization, and workflow efficiency, informed by input from more than 100 vessel harvesting specialists worldwide. A redesigned Harvesting Tool features an ergonomic, game-controller-style handle and a soft-touch Activation Toggle that allows activation with minimal force and multiple hand positions, supporting clinician comfort and control throughout the procedure. The system also introduces simplified connectivity through an integrated Harvesting Tool Power Cable, providing a one-click connection to the new Vasoview Hemopro 3 Power Supply and eliminating the need for extension cable sterilization. The dedicated Power Supply is designed to deliver consistent energy and promote efficient cut-and-cautery performance with minimal downtime. Hemopro 3 includes features which support consistent visibility, safety, and workflow efficiency during EVH. Vasoview Hemopro 3 is launching in the U.S., with a training supported rollout available for U.S. customers. Getinge plans a phased expansion outside the U.S., with availability in additional markets to follow based on regulatory approvals and market readiness. Vasoview Hemopro 2 will continue to be available as Getinge rollout availability of Vasoview Hemopro 3.
Recent Insider Transactions • May 31CEO, President & Director recently bought €436k worth of stockOn the 29th of May, Mattias Perjos bought around 25k shares on-market at roughly €17.43 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Mattias has been a buyer over the last 12 months, purchasing a net total of €715k worth in shares.
Valuation Update With 7 Day Price Move • May 22Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €18.75, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 19x in the Medical Equipment industry in Italy. Total returns to shareholders of 8.3% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €32.79 per share.
New Risk • May 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.2% average weekly change).
공시 • Apr 22+ 1 more updateGetinge AB (publ) Approves Dividend, Payable from April 28, 2026Getinge AB (publ) approved the Dividend payment at its Annual General Meeting held on April 21, 2026. In accordance with the proposal by the Board of Directors and the CEO, the AGM resolved to declare a dividend of SEK 4.75 per share. April 23, 2026 was determined as record date for dividend. The dividend is expected to be distributed by Euroclear Sweden AB starting April 28, 2026.
공시 • Apr 10Getinge AB (publ) (OM:GETI B) acquired Pennamed Limited.Getinge AB (publ) (OM:GETI B) acquired Pennamed Limited on April 8, 2026. The acquisition strengthens Getinge’s offering to endoscopy units across the United Kingdom (UK) by combining Pennamed’s established consumables portfolio and strong customer relationships with Getinge’s expertise in endoscope reprocessing, infection control, and washer-disinfector technology. Getinge and Pennamed has combined 350 employees. Abi Godfrey, Alex Parry and Matt Harvey of Grant Thornton UK LLP acted as accountants for Pennamed Limited. Emma Orriss and Nigel Beckwith of Gosschalks LLP acted as legal advisors for Pennamed Limited. Covington & Burling Llp acted as legal advisor and Ernst & Young AB acted as accountant for Getinge AB. Getinge AB (publ) (OM:GETI B) completed the acquisition of Pennamed Limited on April 8, 2026.
공시 • Mar 26+ 3 more updatesGetinge AB (publ) to Report Q2, 2026 Results on Jul 17, 2026Getinge AB (publ) announced that they will report Q2, 2026 results on Jul 17, 2026
공시 • Mar 12Getinge AB (publ) Announces Malin Persson Declines Re-Election as Board Member, Effective April 21, 2026Getinge AB (publ) at its Annual General Meeting to be held on April 21, 2026, announced Malin Persson has declined re-election as board member.
Declared Dividend • Feb 24Dividend of kr4.75 announcedShareholders will receive a dividend of kr4.75. Ex-date: 22nd April 2026 Payment date: 28th April 2026 Dividend yield will be 25%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (57% earnings payout ratio) and cash flows (49% cash payout ratio). The dividend has increased by an average of 5.4% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 47% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Board Change • Feb 24Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 7 highly experienced directors. Director Ulrika Dellby was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Jan 28Getinge AB (publ), Annual General Meeting, Apr 21, 2026Getinge AB (publ), Annual General Meeting, Apr 21, 2026.
공시 • Jan 27Getinge AB (Publ) Proposes DividendGetinge AB (publ) announced the proposal of dividend per share of SEK 4.75 (4.60).
공시 • Dec 19Getinge AB Announces Malin Persson Declines Re-Election to the BoardGetinge AB announced that Malin Persson, a board member since 2014, has announced that she will not be available for re-election to the board in 2026.
Board Change • Dec 11Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 7 highly experienced directors. Director Ulrika Dellby was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 19Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 7 highly experienced directors. Director Ulrika Dellby was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Oct 21Getinge AB (Publ) Reaffirms Earnings Guidance for the Year 2025Getinge AB (publ) reaffirmed earnings guidance for the year 2025. The company remain with expectation for organic net sales growth to be in the range of 2% to 5% and long-term financial target of over 12% EPS growth is also intact despite the headwind from tariffs and currency.
Reported Earnings • Jul 21Second quarter 2025 earnings released: EPS: kr1.92 (vs kr1.88 in 2Q 2024)Second quarter 2025 results: EPS: kr1.92 (up from kr1.88 in 2Q 2024). Revenue: kr8.24b (flat on 2Q 2024). Net income: kr524.0m (up 2.1% from 2Q 2024). Profit margin: 6.4% (up from 6.2% in 2Q 2024). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Italy.
공시 • Jul 02Getinge AB (publ)(OM:GETI B) dropped from OMX Stockholm 30 IndexGetinge AB (publ) has been dropped from the OMX OMX Stockholm 30 Index
공시 • Apr 23+ 1 more updateGetinge AB (publ) Approves Dividend, Payable on April 29, 2025Getinge AB (publ) at its AGM held on April 22, 2025 approved dividend of SEK 4.60 per share. April 24, 2025 was determined as record date for dividend. The dividend is expected to be distributed by Euroclear Sweden AB starting Tuesday April 29, 2025.
공시 • Mar 28+ 1 more updateGetinge AB (publ) to Report Q3, 2025 Results on Oct 21, 2025Getinge AB (publ) announced that they will report Q3, 2025 results on Oct 21, 2025
공시 • Mar 18Getinge Introduces Neural Pressure Support for the Servo-U Ventilator SystemGetinge announces the launch of its latest innovation in ICU ventilation – Neural Pressure Support (NPS) – available for both invasive and non-invasive ventilation. Building on its most personalized ventilation modes, NAVA and NIV NAVA, these two new NPS modes offer clinicians more options to provide personalized ventilation that aims to protect both the lungs and diaphragm. For years, Getinge has been market-driving when it comes to developing first-of-its-kind intensive care ventilation modes. The medtech company is introducing NPS and NIV NPS to widen its neurally controlled ventilation offering. The new Neural Pressure Support modes give clinicians the opportunity to deliver classical pressure support ventilation, enhanced with neural trigger and breath termination in synchrony with diaphragmatic muscle activity. This may be particularly beneficial for complex and challenging ICU patient groups, such as obstructive COPD patients requiring instant synchronization and fast pressurization, and restrictive ARDS patients with stiff lungs and an excessive respiratory drive.
공시 • Jan 29Getinge AB (publ), Annual General Meeting, Apr 22, 2025Getinge AB (publ), Annual General Meeting, Apr 22, 2025. Location: halmstad Sweden
공시 • Dec 10Getinge AB (publ) to Report Q1, 2025 Results on Apr 22, 2025Getinge AB (publ) announced that they will report Q1, 2025 results on Apr 22, 2025